Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016-Reference-Cited by-同舟云学术

Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016

Published:2016-03-17 Issue:11 Volume:21 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Chambers Catharine¹,Skowronski Danuta M¹²,Sabaiduc Suzana¹,Winter Anne Luise³,Dickinson James A⁴,De Serres Gaston⁵⁶⁷,Gubbay Jonathan B³⁸,Drews Steven J⁹¹⁰,Martineau Christine⁵,Eshaghi Alireza³,Krajden Mel¹²,Bastien Nathalie¹¹,Li Yan¹¹¹²

Affiliation:

1. British Columbia Centre for Disease Control, Vancouver, Canada

2. University of British Columbia, Vancouver, Canada

3. Public Health Ontario, Toronto, Canada

4. University of Calgary, Calgary, Canada

5. Institut National de Santé Publique du Québec (National Institute of Health of Quebec), Québec, Canada

6. Laval University, Quebec, Canada

7. Centre Hospitalier Universitaire de Québec (University Hospital Centre of Quebec), Québec, Canada

8. University of Toronto, Toronto, Canada

9. Alberta Provincial Laboratory, Edmonton, Canada

10. University of Alberta, Edmonton, Canada

11. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

12. University of Manitoba, Winnipeg, Canada

Abstract

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2015/16 vaccine effectiveness (VE) against influenza A(H1N1)pdm09 viruses. Adjusted VE showed significant protection of 64% (95% confidence interval (CI): 44–77%) overall and 56% (95%CI: 26–73%) for adults between 20 and 64 years-old against medically attended, laboratory-confirmed A(H1N1)pdm09 illness. Among the 67 A(H1N1)pdm09-positive specimens that were successfully sequenced, 62 (> 90%) belonged to the emerging genetic 6B.1 subclade, defined by S162N (potential gain of glycosylation) and I216T mutations in the haemagglutinin protein. Findings from the Canadian SPSN indicate that the 2015/16 northern hemisphere vaccine provided significant protection against A(H1N1)pdm09 illness despite genetic evolution in circulating viruses.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference29 articles.

1. Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine.;Appiah;MMWR Morb Mortal Wkly Rep,2015

2. Update: influenza activity – United States, October 4, 2015-February 6, 2016.;Russell;MMWR Morb Mortal Wkly Rep,2016

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age-Specific Etiology of Severe Acute Respiratory Infections and Influenza Vaccine Effectivity in Prevention of Hospitalization in Russia, 2018–2019 Season;Journal of Epidemiology and Global Health;2021-10-28

2. Regional differences in vaccine uptake and serological responses to vaccine and circulating strains of H1N1 viruses among patients with confirmed influenza;Journal of Clinical Virology Plus;2021-09

3. Maternal Vaccination and Infant Influenza and Pertussis;Pediatrics;2021-09-01

4. Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study;Infection Control & Hospital Epidemiology;2021-05-06

5. Interim seasonal influenza vaccine effectiveness estimates as proxy for final estimates: analysis of systematically identified matched pairs of interim/final estimates from test-negative design studies in outpatient settings from 2010/11 to 2018/19;Expert Review of Vaccines;2021-04-01